Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes

Since 2013, a new drugs-of-abuse trend attempts to bypass drug legislation by marketing isomers of scheduled synthetic cannabinoids (SCs), e.g., FUBIMINA (BIM-2201) and THJ-2201. It is much more challenging to confirm a specific isomer’s intake and distinguish it from its structural analog because t...

Descripción completa

Detalles Bibliográficos
Autores principales: Diao, Xingxing, Scheidweiler, Karl B., Wohlfarth, Ariane, Zhu, Mingshe, Pang, Shaokun, Huestis, Marilyn A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971051/
https://www.ncbi.nlm.nih.gov/pubmed/27547265
http://dx.doi.org/10.1007/s11419-016-0312-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971051/
https://www.ncbi.nlm.nih.gov/pubmed/27547265
http://dx.doi.org/10.1007/s11419-016-0312-2

Ejemplares similares